Craig-Hallum downgraded Ironwood (IRWD) to Hold from Buy with a price target of $1, down from $7, as the risk-reward has changed following the company’s update that the FDA will require a second Phase 3 trial for apraglutide, delaying potential approval to ~2029. The requirement in part stems from lower-than-expected drug exposure in the STARS study due to dose preparation issues, a newly disclosed issue. Timing of material apraglutide revenues will now likely not line-up with Linzess LOE, presenting challenges, the firm says. The extra trial will require funding, limit EBITDA growth, reduce potential debt paydown before Linzess LOE, and this plus the apraglutide delay makes refinancing the June 2026 convertible notes more complicated, argues Craig-Hallum. While strategic alternatives are being explored, uncertainty is much higher now, it adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRWD:
- Ironwood Pharma: Hold Rating Amid Uncertainty Over Apraglutide’s Phase 3 Trial and Strategic Options
- Ironwood downgraded to Hold from Buy at Jefferies
- Hold Rating on Ironwood Pharma Amid FDA Trial Requirements and Strategic Uncertainties
- Ironwood downgraded to Equal Weight from Overweight at Wells Fargo
- Wells downgrades Ironwood to Equal Weight on ‘major setback’